MultiSENSory Stimulation to TArgeT Sensory Loss and ChronIc Pain in NeurOpathic PatieNts

NCT ID: NCT05483816

Last Updated: 2024-11-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-06-30

Study Completion Date

2028-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Neuropathy is a costly and disabling health issue, which consists of a degeneration of the peripheral nerves. Even though the causes may be different, such as diabetes or amputation, the consequences for neuropathic patients are multiple and extremely debilitating. Among the alarming symptoms it implicates, chronic pain and sensory loss are among the most severe ones. Because of the loss of sensations, patients are forced to have an altered gait strategy, an impaired balance and a fivefold increased risk of falling. Furthermore, since they lose sensations and feel numbness in their extremity, they are discouraged in walking, hence leading to a sedentary lifestyle. All of this is worsened by the development of neuropathic pain, which has a high comorbidity with psychological issues, such as depression and anxiety.

Today, proper treatments for neuropathic pain that exclude pharmacological solutions are still missing. This is due to the complexity of the neurobiological mechanisms underlying the origin of neuropathy, the multifaceted physical and psychological nature of pain and the lack of reliable biomarkers.

The aim of this project is to tackle the major problems connected to neuropathy thanks to non-invasive stimulation of the peripheral nervous system. The system is composed of an insole with pressure sensors that captures in real time the force exerted by the subject on the foot and couples this information with parameters of electrical stimulation. Thanks to optimal electrode placement and intensity modulation, subjects are able to perceive in real-time in a somatotopic manner (i.e., under their foot) how they are walking. The aim now is twofold: first the investigators want to couple this stimulation with Virtual Reality (VR) to develop a neuroadaptive non-invasive brain computer interface (BCI) to treat pain and secondly the investigators want to measure through fMRI scans whether the use of the sensory feedback system allows any beneficial plastic changes in the brain. Finally, the investigators want to measure through fMRI scans whether the use of the sensory feedback system allows any beneficial plastic changes in the brain.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

One of the notoriously hardest and long-established challenges for the whole scientific community concerns the complete understanding and, consequently, the treatment of neuropathy. This condition results in an altered gait strategy, an impaired balance and a fivefold increased risk of falling. Falling is one of the major health-related problems. In the United Kingdom, more than one fourth of accidents requiring hospital treatment are a consequence of falls. Furthermore, since they lose sensations and feel numbness in their extremity, they are discouraged in walking, hence leading to a sedentary lifestyle (which promotes other long-term complications, e.g. of the cardiovascular system). This has also very severe impacts on the patients' psychological health. Indeed, the comorbidity of neuropathy with anxiety and depression has been estimated to be 59% in the U.S population. Patients may develop neuropathic pain, associable to the aberrant sensory inputs. Experiencing pain impacts even more on gait stability and on the fear of falling. Given the complexity of the underlying mechanisms, chronic neuropathic pain is one of the most prevalent, costly and disabling health issue, hitting a huge portion of the world population. Chronic pain, indeed is estimated to affect approximately 19% of the adult European population. Nowadays, current chronic pain therapies (either behavioural, pharmacological or surgical) are inefficient, as demonstrated by the high prevalence, low rates of functional recovery and the assiduous reliance on opioid analgesics.

The reasons of such lack of efficacy can be attributed to different factors, among which the lack of therapies addressing the multidimensions of pain, as pain is not a unitary phenomenon, rather a multidimensional outcome of sensory-discriminative and motivational-affective components, that should be synergistically accounted for, and the lack of reliable biomarkers: objective indicators of pain are needed to demonstrate therapeutic target engagement, to stratify patients and to predict disease progression or therapeutic responses.

These factors are the main focuses of this study, whose aim is to develop a multisensory platform for pain, detecting pain through physiological recordings and delivering a therapy when such physiological biomarkers are detected. First the detection of pain is exploited through electrophysiology and then the therapy is delivered by means of Virtual Reality (VR) and Transcutaneous Electrical Nerve Stimulation (TENS), in order to target both physiological and affective/cognitive components of neuropathic pain. VR and TENS have already singularly produced encouraging results in literature\[26-29\]. However, these results are conflicting and not conclusive. The investigators believe that the combination of these technologies, which targets all the different aspects of pain, will really provide a successful and lasting benefit to the patients chronic pain.

Furthermore, the nature of the platform, which includes the use of non-invasive electrical stimulation, allows to recreate sensations in parts of the body where the subjects don't feel sensations anymore. Indeed, thanks to years of research, the Neuro-engineering laboratory found optimal stimulation parameters and electrode placement which are able to elicit sensations far from the electrodes placement. Electrodes are indeed placed on healthy parts of the nerves, but the perceived sensation is in the extremities. This allows to target also another extremely common consequence of neuropathy: sensory loss. This symptom forces patients to have an altered gait strategy, impaired balance and a five-fold increased risk of falling. Therefore, in this study the investigators will monitor also the potential benefits of the platform on these aspects.

As for the imaging sessions, before starting the imaging sessions, patients will be assessed to obtain potential information that might impact on the results.

Healthy participants and patients will be asked to participate in two-three fMRI sessions. Prior to the scanning, a calibration procedure will take place, to understand the subject's stimulation parameters and characterize the location and type of sensations elicited.

During the fMRI sessions, the investigators will examine the neural correlates of the referred perceptions and any pain relief induced using the non-invasive TENS stimulation approach. During these sessions different types of stimulations will be performed (with the TENS stimulation system, with vibrotactile stimulators, and with visual stimulations). Resting state fMRI will be used to examine functional connectivity between different regions of interest. Each fMRI session will last \~70-80 minutes.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neuropathy Neuropathy, Painful Sensory Neuropathy Diabetic Neuropathies Amputation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Caregivers Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Virtual Reality and Transcutaneous Electrical Nerve Stimulation

for healthy subjects: painful stimulus induction (electrical stimulation) for patients: focus/non focus on pain

Therapy is released in presence of pain

Group Type EXPERIMENTAL

VR+TENS

Intervention Type COMBINATION_PRODUCT

The subjects will receive a therapy that combines electrical pleasant stimulation of the nerves, synchronised with event in virtual reality

Virtual Reality only

only VR delivers therapy

Group Type ACTIVE_COMPARATOR

VR+TENS

Intervention Type COMBINATION_PRODUCT

The subjects will receive a therapy that combines electrical pleasant stimulation of the nerves, synchronised with event in virtual reality

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

VR+TENS

The subjects will receive a therapy that combines electrical pleasant stimulation of the nerves, synchronised with event in virtual reality

Intervention Type COMBINATION_PRODUCT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18-80
* Visual acuity\>6 on Snellen visual acuity chart
* Exclusion:

* Pregnancy
* Cognitive deficits (Mini Mental State Examination\<23)
* Cyber-sickness
* Prior or current psychological diseases
* Pacemakers
* Epilepsy
* Claustrophobia
* Other MRI contraindications
* Unhealed fractures
* Unhealed wounds
* Cancerous growth in proximity to feet
* Swollen, infected or inflamed areas on feet or skin eruptions on feet such as phlebitis, thrombophlebitis or varicose veins

for patients:

* Inclusion:

* Age 18-80
* Visual acuity\>6 on Snellen visual acuity chart
* Diagnosis of peripheral neuropathy
* Pain in lower limbs\>=3 cm on VAS scale
* Exclusion:

* Pregnancy
* Relevant comorbidities that would affect the outcomes of the study (by judgement of physicians)
* Ulcers
* Cognitive deficits (Mini Mental State Examination\<23)
* Cyber-sickness
* Prior or current psychological diseases
* Pacemakers
* Epilepsy
* Claustrophobia
* Other MRI contraindications
* Unhealed fractures
* Unhealed wounds
* Cancerous growth in proximity to feet
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Neural Control of Movement laboratory ETH Zurich

UNKNOWN

Sponsor Role collaborator

ETH Zurich

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Stanisa Raspopovic

Prof. Dr. Stanisa Raspopovic

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Stanisa Raspopovic, Prof. Dr.

Role: PRINCIPAL_INVESTIGATOR

ETH Zurich

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

ETH Zurich

Zurich, Canton of Zurich, Switzerland

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Switzerland

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Stanisa Raspopovic, Prof. Dr.

Role: CONTACT

44 632 58 39 ext. +41

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Stanisa Raspopovic, Prof. Dr.

Role: primary

44 632 58 39 ext. +41

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NeuroengLab

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Diabetic Neuropathy Topical Treatment
NCT00661063 UNKNOWN PHASE3